11 results about "Prophylactic treatment" patented technology

The present invention relates to a DHP-I inhibitor for use in a method for the prophylactic and / or therapeutic treatment of a neuroinflammatory disease. In some embodiments, it relates to a DHP-I inhibitor for use in a method for the prophylactic treatment of neurodegeneration. The present invention also relates to a DHP-I inhibitor for use as neuroprotectant. It further pertains to related methods for the prophylactic and / or therapeutic treatment of a neuroinflammatory disease and the use of a DHP-I inhibitor in the manufacturing of a medicament for use in these methods. The present invention also provides pharmaceutical compositions and delivery systems for use in the methods of the invention, as well as to a pharmaceutical composition or drug delivery systems suitable for administration by a route bypassing the blood brain barrier (BBB) and / or the blood retinal barrier (BRB), preferably selected intrathecal, intracranial, intranasal and / or ocular administration; or suitable for trespassing the BBB and / or the BRB.

Compositions and principles for use before parturition in the prophylactic treatment of hypocalcemia in ruminant animals include compositions having phosphate binders for the prophylactic treatment of parturient hypocalcemia in ruminant animals. These compositions are presented in unit dosage forms, with one or more doses administered daily to the gastrointestinal tract of the ruminant animal, or in wet form. The composition contains one or more phosphate binders and one or more nutrients selected from minerals, vitamins, and amino acids, as well as a composition that includes an inhibitor of the small intestinal Na-phosphate transporter for the prophylactic treatment of parturient hypocalcemia in ruminant animals. Phosphate binders are selected from aluminum, iron, sevelamer, and lanthanum salts, with either inorganic or organic acids, hydrates thereof, or any mixture thereof.

Provided herein include compounds, compositions, kits and methods for preventing and treating psychiatric disorders. The composition and methods described herein can prophylactically treat a subject prior to and / or after a stressor and / or prior to the recurrence of a stressor, thereby preventing or delaying a relapse of depression or depression-like and / or stress-induced behaviors and disorders. The composition can comprise a serotonin 4 receptor (S-HUR) agonist and an N- methyl-D-aspartate (NMDAR) antagonist and a pharmaceutically acceptable salt, analog, derivative or metabolite thereof.

The application provides a miniaturized device for lower limb blood flow intervention using neuromuscular electrical stimulation, which comprises a special intervention layer plate, a muscle pump group layer plate and a micro electrical intervention component; an adapter belt is arranged between the special intervention layer plate and the muscle pump group layer plate and is connected with the special intervention layer plate and the muscle pump group layer plate, and the adapter belt is used for annular fixation of the knee joint; the special intervention layer plate and the muscle pump group layer plate both comprise a layer-by-layer attached air pressure layer, a circuit layer and an adhesive layer, the adhesive layer is in contact with the skin surface, the air pressure layer is connected with an air inlet and outlet assembly at an air inlet end, a plurality of conductive modules are arranged in the circuit layer and are electrically connected with the micro electrical intervention component, the air pressure layer is used for extruding the conductive module to tightly contact the skin, and the contact surface of the conductive module and the skin are in contact through the adhesive layer; the device fuses the pneumatic and electrical stimulation in the miniaturized device, so that the lower limb venous dysfunction patient can more conveniently perform preventive treatment and follow-up treatment on the lower leg, and the risk of lower limb venous embolism is reduced.

The invention provides application of p-hydroxycinnamic acid in preparation of a medicine for preventing and treating noise-induced deafness. The invention has the advantages that the p-hydroxycinnamic acid has the advantages of strong pertinence, high safety, convenience in medication, good patient compliance and the like, not only effectively overcomes the defects of the existing noise-induced hearing loss treatment medicines, but also provides a brand-new preventive treatment thought; important clinical popularization significance and industrial application prospects are realized.

The present invention relates to a composition comprising a transfection agent and a human endogenous retrovirus (HERV) envelope protein having a mutation in its immunosuppressive domain (ISD) that reduces its immunosuppressive properties, or mRNA encoding at least the immunogenic portion thereof. The present invention also relates to the manufacture of pharmaceuticals and the use of this composition in therapeutic and prophylactic treatments.

Anti-parasitic compounds and uses thereof. Compounds comprising a C-terminal peptide adjuvant conjugated to an N-terminal peptide antigen via a protease-cleavable linker, said peptide adjuvant comprising a peptide analog of C5a, wherein said peptide antigen comprises an antigenic epitope of a parasitic organism, such as T. gondii. Methods of therapeutic or prophylactic treatment of a parasitic infections.

The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.

The present invention relates to compositions comprising microorganisms for use in reducing blood urate concentration. These compositions can be used in the therapeutic and prophylactic treatment of subjects at risk of, or suffering from, elevated blood urate levels. The compositions can be pharmaceutical or nutraceutical compositions for the treatment and prevention of urate and hyperuricemia related diseases such as cardiovascular disease, metabolic syndrome, non-alcoholic fatty liver disease, chronic kidney disease, gout, insulin resistance, hypertension, dyslipidemia, renal insufficiency, obesity, prediabetes and diabetes.

A nanosystem and methods of treating, including prophylactically, coronavirus infections, such as those caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by administering such nanosystem to a patient is presented. The nanosystem may be comprised of a single or a combination of therapeutic agents, optionally encapsulated in a nanoparticle having a targeting moiety directed to the particular coronavirus. For CoV-2 infections, at least one therapeutic agent, such as the dual DPP4 / ACE2 inhibitor sitagliptin, may optionally be encapsulated within a nanoparticle having a fatty acid such as linoleic acid, as the targeting moiety. Administration can occur intranasally prior to infection for prophylactic treatment or post-infection for treatment of the viral infection.

This invention belongs to the field of traditional Chinese medicine and discloses the application of total saponin extracts from *Abrus precatorius* in the preparation of drugs for treating and preventing liver injury caused by immune checkpoint inhibitors. This invention is the first to use total saponins from *Abrus precatorius* for preventative treatment of liver injury caused by immunosuppressants and has demonstrated significant efficacy. After preventative treatment with total saponins from *Abrus precatorius*, liver injury caused by immunosuppressants was significantly alleviated in Pdcd1 knockout C57BL / 6 mice, with a significant decrease in ALT and AST levels and a significant reduction in hepatic immune infiltration. Furthermore, transcriptome sequencing analysis showed that total saponins from *Abrus precatorius* mainly exert their pharmacological effects by inhibiting the activation of the cGAS-STING pathway, indicating that preventative administration of total saponins from *Abrus precatorius* can alleviate the pathological state and inflammatory level of ICI liver injury, thus showing promise for practical application.